What Does the Science Actually Say About Regenerative Medicine in Aesthetic Practice?
The term regenerative medicine has become one of the most used and most loosely applied in aesthetic medicine. Here is a rigorous examination of what it actually means, which treatments genuinely qualify, and where the science is heading next.
Defining the territory
Regenerative medicine, properly understood, refers to interventions that restore, maintain, or enhance the biological processes responsible for tissue repair and renewal — rather than substituting for them with exogenous material or temporarily modifying their expression.
Applied to aesthetic medicine, this distinction has real clinical significance. A treatment that stimulates fibroblasts to produce new collagen is doing something categorically different from one that places collagen-mimicking material in the tissue. A treatment that activates the body's own repair signalling pathways is doing something categorically different from one that covers the visible surface expression of their decline.
Regenerative aesthetic medicine has rapidly evolved from a primarily corrective discipline into a biologically oriented field focused on restoring tissue function, quality, and homeostasis.
The principal injectable modalities currently described as regenerative include platelet-rich plasma, polynucleotides, exosomes, stromal vascular fraction-based approaches, poly-L-lactic acid, and calcium hydroxylapatite — interventions that act through distinct yet partially overlapping mechanisms, involving modulation of inflammation, fibroblast activation, extracellular matrix remodelling, angiogenesis, and immunobiological signalling.
That is a coherent and clinically useful framework. It is also, as we shall examine, applied with considerably varying degrees of evidential rigour across the different treatment categories operating under the regenerative medicine label.
Polynucleotides — the strongest injectable evidence base
Polynucleotides and their closely related form polydeoxyribonucleotide (PDRN) occupy the most scientifically credible position within regenerative aesthetic medicine. Their mechanism of action is well characterised — activation of adenosine A2A receptors, stimulation of fibroblast proliferation, promotion of collagen synthesis, tissue repair, and anti-inflammatory modulation and the clinical evidence for improvements in skin quality, hydration, luminosity, and tissue regeneration is real, accumulating, and derived from multiple independent research groups.
What distinguishes polynucleotide injectable treatment from many of its competitors in the regenerative space is the coherence between the proposed mechanism and the observed clinical outcomes. The biology explains the results. That explanatory coherence, often absent in treatments where the mechanism is speculative or the claimed effect biologically implausible, is one of the most reliable markers of a treatment with genuine scientific foundation.
The questions that remain open, principally the long-term durability of results and the degree to which different product formulations produce meaningfully different clinical outcomes are the kind of questions that responsible clinical investigation should be asking. They are not reasons to dismiss the treatment. They are reasons to continue examining it with appropriate rigour.
Biostimulators — mature science with established evidence
Poly-L-lactic acid (Sculptra) and hyaluronic acid biostimulators (Profhilo) represent the most established corner of regenerative aesthetic medicine. They are treatments with years of clinical evidence, well-characterised mechanisms, and a track record of peer-reviewed validation that newer entrants to the regenerative space are not yet able to match.
PLLA (Sculptra) works through a controlled foreign body response, namely immune-mediated activation of fibroblasts producing new type I and type III collagen over months following injection. The biology is precise, the evidence is robust, and the clinical results in appropriate patients are among the most durable non-surgical outcomes available in aesthetic practice. CaHA (Radiesse) operates through direct fibroblast activation via scaffold contact — a mechanistically distinct pathway from PLLA, as we discussed in our Sculptra versus Radiesse piece, producing comparable neocollagenesis with different rheological properties and a different clinical profile.
These are not frontier treatments operating at the edge of the evidence base. They are evidence-based clinical tools with established safety profiles, reproducible outcomes, and a scientific foundation that deserves more serious recognition within the regenerative medicine conversation than the newer, more excitable entrants tend to attract.
Platelet-rich plasma — legitimate biology, variable execution
The principal challenge is not conceptual but technical. PRP preparation protocols vary enormously between clinics and devices — in centrifugation speed and duration, final platelet concentration, leukocyte inclusion or exclusion, and activation method. These variables have clinically meaningful effects on the growth factor content of the final product, and the inconsistency between preparation methods makes comparison between studies, and between clinical results, genuinely difficult. Two clinics both offering PRP may be delivering preparations with very different biological activity. The label does not standardise the product.
Exosomes — fascinating biology, premature clinical confidence
Exosomes, nanoscale extracellular vesicles secreted by cells and carrying a cargo of growth factors, micro-RNAs, proteins, and signalling molecules, represent one of the most intellectually exciting areas in regenerative medicine. Exosomes function as cell-to-cell communicators, not as raw repair substrate. The mechanism is signalling, not material supply. Mesenchymal stem cell-derived exosomes have demonstrated capacity to deliver growth factors, miRNA, and proteins directly to skin cells to drive cutaneous regeneration through pathways including PI3K/Akt, Wnt/beta-catenin, and TGF-beta/Smad signalling.
The injectable exosome evidence is developing rapidly, particularly in the context of post-procedure recovery and wound healing acceleration. The topical exosome story is considerably more complicated, and considerably more marketed. Whether topically applied exosomes penetrate the skin barrier in biologically meaningful quantities, whether they retain biological activity after manufacturing and formulation, and whether the cell source and preparation method produce a standardised and reproducible preparation, are questions that the clinical literature has not yet answered satisfactorily.
The marketing confidence around exosomes, particularly topical preparations, currently significantly exceeds the evidence base. That does not make the biology uninteresting or the injectable applications clinically irrelevant. It makes the gap between promise and proof a clinical concern that deserves honest acknowledgement.
Cellular senescence — the genuine frontier
The most intellectually compelling frontier in regenerative aesthetic medicine does not yet have a clinical application. It sits in the laboratory, moving towards translation with a pace and rigour that suggests it may eventually arrive in clinical practice with considerably more evidential credibility than some of the treatments currently marketed as cutting edge.
Cellular senescence, the accumulation of permanently cell-cycle-arrested cells that secrete a chronic inflammatory cocktail known as the senescence-associated secretory phenotype (SASP), is now recognised as a central driver of skin ageing. The accumulation of dysfunctional senescent cells is one of the important mechanisms of skin aging, based on which a series of anti-aging strategies have been generated. Senescent fibroblasts not only fail to produce collagen but actively promote its degradation through the MMPs and cytokines they secrete — a self-perpetuating cycle of deterioration that sits at the biological root of many of the changes aesthetic medicine is trying to address.
Senolytics, agents that selectively eliminate senescent cells, represent a genuinely novel approach to this problem. Preclinical work has demonstrated that topical senolytic compounds can reduce senescence markers in aged skin and accelerate wound closure. Cellular senescence in human skin ageing and the potential for leveraging senotherapeutics represents an area of active investigation at major research centres including the Mayo Clinic, with Jean Carruthers, whose ground-breaking work on cosmetic botulinum toxin, is among the authors of a 2024 paper on this subject. The serendipity of that connection is not lost on us.
The human clinical evidence for senolytics in skin ageing remains early and predominantly preclinical. The translational pathway is genuinely uncertain. But the biology is mechanistically coherent, the laboratory evidence is compelling, and the field is attracting serious scientific investment. This is what a genuine scientific frontier looks like — before the marketing arrives.
The question the label cannot answer
The fundamental limitation of regenerative medicine as a clinical category is that the label conveys a mechanism rather than an outcome. A treatment that genuinely stimulates biological repair, produces durable tissue regeneration, and can demonstrate those outcomes through independent, well-designed clinical trials belongs in a different clinical category from one that invokes the language of regeneration to describe an effect whose evidence base is thin, manufacturer-funded, or primarily in vitro.
Both may be described as regenerative medicine. The label does not distinguish between them. The questions that do distinguish between them are the ones we have outlined in our Evidence Problem piece — and they apply here with full force. The most important skill available to a practitioner navigating the regenerative medicine landscape is not familiarity with the latest treatment but the ability to apply consistent scientific scepticism to every new arrival, regardless of how compelling the biology sounds and how impressive the marketing looks.
The honest assessment
Regenerative medicine in aesthetic practice is neither the revolution its most enthusiastic advocates claim nor the sophisticated marketing exercise its sceptics sometimes suggest. It is a genuinely heterogeneous field, containing treatments at very different stages of scientific development, united by a biological philosophy that is sound even where the specific clinical evidence remains incomplete.
The treatments with the most established evidence, biostimulatory injectables, polynucleotides, PRP in appropriate indications, deserve to be used with confidence and continued clinical investigation.
The treatments at the frontier, injectable exosomes, senolytic approaches, deserve serious scientific attention and appropriate clinical caution.
The treatments where marketing has most decisively outpaced evidence, topical exosomes, stem cell extracts, many of the ingredients currently appearing under the regenerative medicine label in premium skincare, deserve the same critical scrutiny we would apply to any other claim that has not been adequately validated.
That graduated, evidence-calibrated approach is what responsible engagement with regenerative medicine looks like. It is also, not coincidentally, what responsible engagement with any area of medicine looks like.
The views expressed in Clinical Perspectives are the author's own and reflect their personal and professional experience in aesthetic medicine.
References
Guida S et al. What "regenerative" means in aesthetic medicine: a narrative literature review attempting to demystify the core essence of regenerative aesthetics. Plastic and Aesthetic Research. 2026. https://www.oaepublish.com/articles/2347-9264.2025.127
Haykal D et al. Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges. Journal of Drugs in Dermatology. 2025;24(1):12–18.
https://pubmed.ncbi.nlm.nih.gov/39761139/Wyles SP, Carruthers JD et al. Cellular Senescence in Human Skin Aging: Leveraging Senotherapeutics. Gerontology. 2024;70(1):7–14. https://pmc.ncbi.nlm.nih.gov/articles/PMC10873061/
Chen X et al. Cellular Senescence and Anti-Aging Strategies in Aesthetic Medicine: A Bibliometric Analysis and Brief Review. Clinical, Cosmetic and Investigational Dermatology. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11471065/
Advances in Longevity: The Intersection of Regenerative Medicine and Cosmetic Dermatology. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12268380/
Ash M et al. The Innovative and Evolving Landscape of Topical Exosome and Peptide Therapies: A Systematic Review. Aesthetic Surgery Journal Open Forum. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11023079/